CSIMarket
 
Cidara Therapeutics Inc   (NASDAQ: CDTX)
Other Ticker:  
 
 
Price: $23.4650 $1.48 6.708%
Day's High: $24.81 Week Perf: 10.53 %
Day's Low: $ 21.74 30 Day Perf: 10.74 %
Volume (M): 126 52 Wk High: $ 28.42
Volume (M$): $ 2,947 52 Wk Avg: $14.78
Open: $21.74 52 Wk Low: $10.00



 Market Capitalization (Millions $) 153
 Shares Outstanding (Millions) 7
 Employees 40
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -122
 Cash Flow (TTM) (Millions $) 91
 Capital Exp. (TTM) (Millions $) 0

Cidara Therapeutics Inc
Cidara Therapeutics Inc is a biotechnology company focused on developing and commercializing novel antifungal and immunotherapy technologies. The company's goal is to address unmet medical needs in the treatment of serious fungal infections and provide innovative solutions for patients with compromised immune systems. Cidara's proprietary technology platforms, CloudbreakTM and Immunotherapy Platforms, aim to improve patient outcomes and reduce the risks associated with existing antifungal therapies. The company is committed to advancing its pipeline of drug candidates and revolutionizing the field of infectious diseases.


   Company Address: 6310 Nancy Ridge Drive, San Diego, 92121 CA
   Company Phone Number: 752-6170   Stock Exchange / Ticker: NASDAQ CDTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
GILD        9.21% 
AMPH   -2.96%    
PFE   -1.17%    
RCUS   -7.76%    
SCYX   -0.86%    
• View Complete Report
   



Announcement

Betting on Tomorrow Cidara Therapeutics Pioneers Influenza Innovation at IDWeek 2024,

Published Wed, Oct 16 2024 12:00 PM UTC

Betting on Innovation: Cidara Therapeutics Bold Step into the Future with CD388 at IDWeek 2024 In the vibrant realm of biotechnology, evaluating success isn t simply about current financials but the potential to reform the healthcare landscape. Cidara Therapeutics, Inc. (Nasdaq: CDTX) stands as a beacon of innovative potential, crafting a narrative of transformation through...

Shares

Cidara Therapeutics Grants New Employee Stock Options: Analyzing the Impact on Shareholders

Published Fri, Oct 4 2024 8:30 PM UTC

In recent news, Cidara Therapeutics, Inc. (Nasdaq: CDTX), a pioneering biotechnology firm renowned for its innovative Cloudbreak platform, announced the allocation of stock options and restricted stock units (RSUs) to Dipesh Bhatt, a new key employee. Utilizing drug-Fc conjugate (DFC) immunotherapies, the company aims to enhance life-saving treatments for severe diseases. Th...

Clinical Study

Cidara Therapeutics Bold Moves Pioneering Influenza Treatment with CD388 and the Cloudbreak? Platform,

Published Wed, Sep 25 2024 12:00 PM UTC

Abstract Cidara Therapeutics, Inc. has recently announced pivotal steps in its strategic focus on the development of CD388, an innovative drug-Fc conjugate (DFC) candidate aimed at combating influenza A and B. This comprehensive review delves into the data presented at the OPTIONS XII for the Control of Influenza Conference, outlining the safety and pharmacokinetics of CD388...

Clinical Study

Cidara Therapeutics Marks Milestones with NAVIGATE Trial Kickoff and Strategic Rezafungin Divestiture,

Published Mon, Sep 23 2024 12:01 PM UTC

Cidara Therapeutics Advances with NAVIGATE Trial and Strategic Divestiture DecisionCidara Therapeutics, Inc. (Nasdaq: CDTX), a pioneering biotechnology company, has recently set significant milestones in its strategic trajectory, including the initiation of a Phase 2b clinical trial and the divestiture of one of its key assets. NAVIGATE Trial for Seasonal Influenza On April...

Management Announcement

Cidara Therapeutics Expands Scientific Advisory Board Amid Financial Losses and Strategic Restructuring to Focus on Influenza Therapy Development,

Published Thu, Sep 19 2024 12:00 PM UTC

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a leading biotechnology company based in San Diego, has recently announced a notable expansion of its Scientific Advisory Board (SAB) by appointing four distinguished experts in the field of infectious diseases: Rick Bright, Ph.D., Philip Krause, M.D., Mario Barro, Ph.D., and Frederick G. Hayden, M.D., FACP. This strategic move aims ...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com